The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Phase 1b study of H3B-6545 in combination with palbociclib in women with metastatic estrogen receptor–positive (ER+), human epidermal growth factor receptor 2 (HER2)-negative breast cancer.
 
Stephen R. D. Johnston
Honoraria - AstraZeneca; Eisai; Lilly; Novartis; Pfizer; Roche
Consulting or Advisory Role - Lilly; Novartis; Pfizer; Puma Biotechnology
Research Funding - Pfizer (Inst); Puma Biotechnology (Inst)
Expert Testimony - Novartis
 
Timothy J. Pluard
Consulting or Advisory Role - AstraZeneca/Daiichi Sankyo; Genentech; H3 Biomedicine; Macrogenics; Novartis; Pfizer; Seagen
Speakers' Bureau - Genentech/Roche; Immunomedics; Novartis; Pfizer; Seagen
Research Funding - Seagen (Inst)
 
Judy S. Wang
Speakers' Bureau - AstraZeneca; Eisai
Research Funding - Acerta Pharma/AstraZeneca (Inst); ADC Therapeutics (Inst); Agenus (Inst); Aileron Therapeutics (Inst); Artios (Inst); AstraZeneca (Inst); AstraZeneca/MedImmune (Inst); Bicycle Therapeutics (Inst); BioNTech (Inst); Birdie (Inst); Boehringer Ingelheim (Inst); Celgene (Inst); CicloMed (Inst); Clovis Oncology (Inst); cyteir (Inst); Daiichi Sankyo (Inst); EMD Serono (Inst); Erasca, Inc (Inst); Evelo Therapeutics (Inst); FORMA Therapeutics (Inst); Genentech/Roche (Inst); GlaxoSmithKline (Inst); H3 Biomedicine (Inst); Hengrui Pharmaceutical (Inst); Hutchison MediPharma (Inst); Ignyta (Inst); Incyte (Inst); Jacobio (Inst); Janssen Research & Development (Inst); Jounce Therapeutics (Inst); Klus Pharma (Inst); Kymab (Inst); Lilly (Inst); Loxo (Inst); LSK BioPharma (Inst); Macrogenics (Inst); Merck (Inst); Mirati Therapeutics (Inst); Moderna Therapeutics (Inst); Pfizer (Inst); Phoenix Pharmaceuticals (Inst); Prelude Therapeutics (Inst); QiLu Pharmaceutical (Inst); Revolution Medicines (Inst); Ribon Therapeutics (Inst); Stemline Therapeutics (Inst); Syndax (Inst); Synthorx (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst); Tesaro (Inst); TopAlliance BioSciences Inc (Inst); Vedanta Biosciences (Inst); Vigeo Therapeutics (Inst); Xencor (Inst)
 
Erika P. Hamilton
Consulting or Advisory Role - Arvinas (Inst); AstraZeneca (Inst); Black Diamond Therapeutics (Inst); Boehringer Ingelheim (Inst); CytomX Therapeutics (Inst); Daiichi Sankyo (Inst); Dantari (Inst); Deciphera (Inst); Eisai (Inst); Genentech/Roche (Inst); H3 Biomedicine (Inst); Lilly (Inst); Merck (Inst); Mersana (Inst); Novartis (Inst); Pfizer (Inst); Puma Biotechnology (Inst); Seagen (Inst); Silverback Therapeutics (Inst)
Research Funding - Abbvie (Inst); Acerta Pharma (Inst); Akeso Biopharma (Inst); Amgen (Inst); ArQule (Inst); Arvinas (Inst); AstraZeneca (Inst); Black Diamond Therapeutics (Inst); Boehringer Ingelheim (Inst); Clovis Oncology (Inst); Compugen (Inst); Curis (Inst); CytomX Therapeutics (Inst); Daiichi Sankyo (Inst); Dana Farber Cancer Hospital (Inst); Deciphera (Inst); eFFECTOR Therapeutics (Inst); EMD Serono (Inst); Fochon Pharmaceuticals (Inst); Fujifilm (Inst); G1 Therapeutics (Inst); Genentech/Roche (Inst); H3 Biomedicine (Inst); Harpoon (Inst); Hutchison MediPharma (Inst); Immunogen (Inst); Immunomedics (Inst); Infinity Pharmaceuticals (Inst); InventisBio (Inst); Karyopharm Therapeutics (Inst); Leap Therapeutics (Inst); Lilly (Inst); Lycera (Inst); Macrogenics (Inst); MedImmune (Inst); Merck (Inst); Mersana (Inst); Merus (Inst); Millennium (Inst); Molecular Templates (Inst); Novartis (Inst); Nucana (Inst); Olema Pharmaceuticals (Inst); OncoMed (Inst); Onconova Therapeutics (Inst); Orinove (Inst); Pfizer (Inst); PharmaMar (Inst); Plexxikon (Inst); Polyphor (Inst); Puma Biotechnology (Inst); Radius Health (Inst); Regeneron (Inst); Rgenix (Inst); Seagen (Inst); Sermonix Pharmaceuticals (Inst); Shattuck Labs (Inst); Silverback Therapeutics (Inst); Stem CentRx (Inst); Sutro Biopharma (Inst); Syndax (Inst); Syros Pharmaceuticals (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst); TapImmune Inc. (Inst); Tesaro (Inst); Torque (Inst); Torque (Inst); Verastem (Inst); Zenith Epigenetics (Inst); Zymeworks (Inst)
 
Dejan Juric
Consulting or Advisory Role - Eisai; EMD Serono; Genentech; Ipsen; MapKure; Novartis; Petra Pharma; Syros Pharmaceuticals; Vibliome Therapeutics
Research Funding - Amgen (Inst); Eisai (Inst); EMD Serono (Inst); Genentech (Inst); Infinity Pharmaceuticals (Inst); InventisBio (Inst); Novartis (Inst); Pfizer (Inst); Placon (Inst); Syros Pharmaceuticals (Inst); Takeda (Inst); Takeda (Inst)
 
Catherine Rose Scholz
Employment - H3 Biomedicine; Kura Oncology
Stock and Other Ownership Interests - Kura Oncology
Patents, Royalties, Other Intellectual Property - METHODS OF TREATING CANCER PATIENTS WITH FARNESYLTRANSFERASE INHIBITORS (FTI treatment of H-Ras mutant cancers), co-Inventor (014168-0011-999) METHODS OF TREATING CANCER PATIENTS WITH FARNESYLTRANSFERASE INHIBITORS (FTI treatment of H-Ras mutant EGFR inhi
Travel, Accommodations, Expenses - Kura Oncology
 
Elizabeth Hnitecki
Employment - H3 Biomedicine
 
Lei Gao
Employment - Eisai
Stock and Other Ownership Interests - Vertex
 
Lisa Cantagallo
Employment - H3 Biomedicine
Stock and Other Ownership Interests - C4 Therapeutics (I); Voyager Therapeutics (I)
 
Manav Korpal
Employment - H3 Biomedicine
Patents, Royalties, Other Intellectual Property - H3 Biomedicine
 
Benoit Destenaves
Employment - AstraZeneca; H3 Biomedicine
Stock and Other Ownership Interests - AstraZeneca
 
Jianjun Alan Xiao
Employment - H3 Biomedicine; Novartis
Stock and Other Ownership Interests - Novartis
Patents, Royalties, Other Intellectual Property - H3 Biomedicine
 
Zhaojie Zhang
Employment - H3 Biomedicine
Stock and Other Ownership Interests - Alnylam (I)
 
J. Marc Marc Pipas
Employment - H3 Biomedicine; Merrimack
Leadership - PanTher Therapeutics
Stock and Other Ownership Interests - Merrimack
Consulting or Advisory Role - PanTher Therapeutics; PanTher Therapeutics
 
Lihua Yu
Employment - H3 Biomedicine
Leadership - H3 Biomedicine
Stock and Other Ownership Interests - AstraZeneca
Honoraria - Flatiron Health; Health Advances
Research Funding - H3 Biomedicine
Patents, Royalties, Other Intellectual Property - H3 Biomedicine
Travel, Accommodations, Expenses - H3 Biomedicine
 
Tarek Sahmoud
Employment - H3 Biomedicine
Leadership - H3 Biomedicine
Stock and Other Ownership Interests - AstraZeneca
Honoraria - Health Advances
Research Funding - H3 Biomedicine
Patents, Royalties, Other Intellectual Property - H3 Biomedicine
Travel, Accommodations, Expenses - H3 Biomedicine
 
Antonio Gualberto
Employment - H3 Biomedicine; H3 Biomedicine; Kura Oncology
Stock and Other Ownership Interests - Kura Oncology
Patents, Royalties, Other Intellectual Property - Patent of HRAS mutation as biomarker for farnesyl transferase inhibitor treatment in HNSCC
Travel, Accommodations, Expenses - Kura Oncology